MDNA11 is a long-acting “beta-only” recombinant interleukin-2 (IL-2) superkine engineered to activate immune effector cells, such as CD8+ T cells and NK cells, which target cancer cells while minimizing the activation of immunosuppressive regulatory T cells. The gene discussed is IL2; the disease is cancer.